Solstice Oncology raises $225M
Solstice Oncology announced a Series A round of $225M on 9 September 2026. The company operates in HealthTech and is based in United States. It was founded by Caroline Loew, Chief Executive Officer. Announced 44 days ago.
Founder
Caroline Loew
Chief Executive Officer, Solstice Oncology
Outreach angles
- -Loew leads Solstice Oncology's launch after a career built on advancing multiple approved oncology medicines from first-in-human trials through registration.
- -Loew is steering Solstice's lead candidate porustobart, a second-generation CTLA-4 antibody, into Phase 2 trials for colon cancer.
- -Solstice Oncology just launched with a $225 million Series A led by RA Capital Management, Canaan Partners, and Forbion.
Signals
Series AHealthcareDeep TechRegulated IndustryNew Market
Round details
Company: Solstice Oncology
Domain: solsticeoncology.com
Amount: $225M
Stage: Series A
Industry: HealthTech
Country: United States
Announced: 9 September 2026
Other HealthTech raises
Recently funded in United States